NCT00098631 - Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

December 31, 2006

Conditions

Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavitySalivary Gland Squamous Cell CarcinomaStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityUntreated Metastatic Squamous Neck Cancer With Occult Primary

Interventions

DRUG

lapatinib ditosylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH